Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

10-02-2026(Tue) 09-02-2026(Mon) 06-02-2026(Fri) 05-02-2026(Thu) 04-02-2026(Wed)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
29 Apr, 2026 (Wednesday)

            
CHINA TELECOM(728)
Analysis¡G
China Telecom is transforming from a traditional telecommunications operator into a ¡§leading artificial intelligence (AI) service provider.¡¨ Although its first-quarter 2026 results were impacted by VAT adjustments and weakness in traditional businesses, leading to a year-on-year decline in net profit of approximately 17.1% to RMB 7.35 billion, its emerging businesses and cash flow control remain key investment highlights.
The Group is capitalizing on the new ¡§AI + Consumption¡¨ upgrade trend, accelerating the integration and upgrading of connectivity, terminals, applications, and benefits. It continues to enhance the intelligent supply of products and services for individual and household users. Its core businesses remain stable, with 5G network users reaching 310 million, a penetration rate of 71.3%. Total mobile data traffic grew 17.7% year-on-year, with mobile data usage per user (DOU) reaching 23GB, up 12.6% YoY. Gigabit broadband user penetration stood at approximately 34%, indicating that data value continues to be realized. On the other hand, the Group has further deepened its integrated intelligent cloud system covering ¡§computing power, platform, data, models, and applications,¡¨ comprehensively advancing the ¡§AI+¡¨ initiative. It is strengthening internal applications and external empowerment, improving operational quality and efficiency, and supporting the digital and intelligent transformation of the economy and society. Its strategic emerging businesses maintained strong momentum, with Tianyi Cloud revenue growing 6.8% year-on-year and intelligent revenue surging 39.4%. Leveraging its cloud-network integration advantages, the Group has secured multiple large AIDC (AI Data Center) contracts worth over RMB 100 million each, effectively driving both existing and new business growth.
In the first quarter, the Group¡¦s net operating cash flow reached RMB 23.2 billion, representing a substantial year-on-year increase of 114.4%, mainly due to strengthened accounts receivable collection and cost control. Total capital expenditure for 2026 is expected to decrease by 9.2% to RMB 73 billion, but the proportion allocated to intelligent fields has increased significantly, showing the company is engaging in ¡§precise spending¡¨ for high-efficiency returns. The Group has positioned AI as its core strategy, with intelligent field investment expected to grow 26% against the trend in 2026, of which AIDC investment is projected to rise 28%. At the same time, it is strategically shifting toward ¡§Token operations.¡¨ With the anticipated explosion of domestic AI applications, intelligent computing demand is expected to drive long-term growth in industrial digitization businesses.(I do not hold the above stock)
Strategy¡G
Buy-in Price: $5.10, Target Price: $5.60, Cut Loss Price: $4.85


PHARMARON(3759)
Analysis¡G
In 2025, the Company's small molecule CDMO (CMC) service revenue reached RMB 3.483 billion (RMB, same below), representing a year-on-year increase of 16.53%. The API production workshops in Ningbo and Shaoxing passed the U.S. FDA's Pre-Approval Inspection (PAI) and, in the fourth quarter, obtained approval for the first commercial production project of an innovative drug API supplying the U.S. market. In Q1 2026, the Company entered into a strategic cooperation agreement with a major international pharmaceutical company to undertake commercial production of its first orally administered small molecule GLP-1 receptor agonist for regulatory submission, marking a significant enhancement in recognition within the high-end international market. In terms of orders, new orders signed in 2025 grew by over 14% year-on-year. Revenue from the world's top 20 pharmaceutical companies reached RMB 2.831 billion (+29.37%), accounting for 20.09% of total revenue. Overseas revenue accounted for 84.84% (North America 61.82%, Europe +27.42%), with global footprint driving revenue growth. The Company added over 950 new clients, serving a total of over 3,300 active clients worldwide. On the policy front, the General Office of the State Council issued the "Several Opinions on Improving the Drug Price Formation Mechanism", establishing a full-chain support system of "innovation premium + multi-payer payment + intelligent regulation", granting independent pricing rights to high-level innovative drugs. With 81 innovative drugs currently in the registration application stage this year, the Company stands at a historic inflection point for industry value pricing. Additionally, the 4th Asia Cell & Gene Therapy Innovation Summit will be held on April 29-30 in Guangzhou, focusing on cutting-edge fields such as cell and gene therapy, which is expected to inject new technological catalysts into the innovative drug industry.
Strategy¡G
Buy-in Price: $21.82, Target Price: $26.02, Cut Loss Price: $19.00



YUTONG (600066 CH) - Exports and Premiumisation Become Core Engines

Company Profile

Yutong is a leading domestic bus manufacturer. Its products cover various market segments including long-distance coaches, tourist coaches, city buses, staff commuter buses, school buses, sightseeing buses, airport shuttle buses, autonomous microcirculation buses, and special-purpose vehicles, meeting market demands across different vehicle lengths from 5 metres to 18 metres. The company has maintained the number one sales volume of large and medium-sized buses in China for 22 consecutive years, securing its industry-leading position.

Investment Summary

FY2025 Net Profit Up 35% yoy; High Dividend Demonstrates Strength
Yutong reported revenue of RMB41.4 billion (RMB, the same below) in 2025, up 11% yoy; net profit attributable to the parent company of RMB5.55 billion, up 35% yoy; and net profit attributable to the parent company excluding non-recurring items of RMB4.58 billion, up 32% yoy. The Company implemented a high dividend plan, with an annual cash dividend of RMB2 per share, together with an interim dividend of RMB0.5 per share, bringing total cash dividends for the year to RMB5,535 million, close to 100% of its RMB5,554 million net profit, fully demonstrating the Company's abundant cash flow and management's commitment to shareholder returns.

Exports and Premiumisation Become Core Engines of Results Growth

Yutong recorded sales volume of 49.5 thousand units in 2025, up 5.5% yoy, of which domestic sales volume was 32 thousand units, down 1.7% yoy; exports were 17 thousand units, up 22.5% yoy, accounting for 34.6% of total sales volume. Among them, exports of new energy buses reached 4,011 units, up 48.6% yoy, accounting for 23.39% of export sales volume, up 4 ppts yoy, while exports of higher-ASP medium and large buses also increased by 22.5% yoy. High export growth and premiumisation of the sales mix drove strong growth in both revenue and profit, serving as the core engines of results growth.

On the expense side, the full-year selling expense ratio/administration expenses ratio/R&D expense ratio were 3.44%/2.02%/4.36%, down 0.18/0.02/0.44 ppts yoy, respectively, reflecting the dual positive effects of product premiumisation and economies of scale. Financial expenses increased by RMB140 million due to reduced foreign exchange gains caused by exchange rate fluctuations. However, asset and credit impairment losses decreased by a total of RMB440 million, boosting profit. The final net profit margin was 13.4%, far exceeding the industry average.

Domestic Weakness and Overseas Strength Drive Gross Margin Expansion

During the period, global penetration of new energy buses continued to increase. Coupled with the Company's advantages in technology, manufacturing, supply chain, service, and cost, this jointly propelled Yutong's export business to a new level.

In 2025, the Company's overseas revenue reached RMB21.1 billion, up 38.87% yoy, with its share of total revenue increasing by approximately 10 ppts to 50.9%. Export ASP reached RMB1.23 million per unit, significantly higher than the domestic level of RMB480 thousand. Export gross margin was 29.6%, up 1.2 ppts yoy, and significantly higher than the domestic level of 19.1%. The expanding export mix drove overall gross margin up 1.2 ppts yoy to 24.14%.

Domestic market revenue of 2025 was RMB15,402 million, down 12.38% yoy, with a gross margin of 19.09%, down 0.28 ppts yoy. This was mainly affected by the normalisation of demand in the domestic tourism market following the earlier recovery, as well as a stabilisation and adjustment of demand. While the urban bus segment achieved slight growth benefiting from the continuation of the "trade-in replacement" policy, while overall demand showed structural divergence.

Accelerated Expansion in Overseas New Energy Bus Segment

Yutong's export business has covered six major regions, including Europe, the Americas, Asia-Pacific, the Middle East, the CIS, and Africa. The Company has achieved bulk exports of new energy buses to more than 60 countries and regions, and has established localised cooperation through KD assembly in more than ten countries and regions, including Kazakhstan, Pakistan, Ethiopia, and Malaysia, forming a global sales network characterised by "multi-polar support and risk diversification", effectively hedging against domestic demand fluctuations. The Company's first overseas new energy vehicle KD plant has been established in Qatar, with an annual production capacity of 300 units, expandable to 1,000 units, supporting continuous expansion in export share and marking a significant acceleration in the Company's overseas new energy expansion. The overall penetration rate of overseas new energy buses is currently only about 15%, leaving substantial room for future growth. The Company's overseas market share is expected to further increase, while the rising share of new energy buses will continue to drive net profit margin improvement.

In addition, the Company's L2--L4 intelligent connected buses have achieved regular operations in 26 domestic cities as well as overseas markets such as Qatar and Singapore, covering multiple scenarios including public transport, industrial parks, and airports. With the accelerated commercialisation of autonomous driving technology, this is expected to further enhance product competitiveness and value-added.

2026Q1, 'Hot Oversea and Chill domestic' Trend Continued

According to the Company's FY2026Q1 result, Yutong's revenue arrived 5.909 billion yuan, down 7.92% yoy; net profit attributable was 659 million yuan, down 12.69% yoy; and net cash flow from operating activities was 3.494 billion yuan, up 146.51% yoy. In terms of sales data, the Company sold a total of 7,652 vehicles in the first quarter, down 15.08% yoy. Domestic market sales were pressured by high base effects and industry adjustments (-29% yoy), while overseas markets (+31% yoy) and new energy bus exports (+57% yoy) continued to perform strongly.

Investment Thesis

The Company's leading position remains solid, with significant economies of scale, mature technology, strong brand recognition, and supply chain advantages. Its performance is expected to sustain steady growth. Yutong has always placed importance on shareholder returns. Since its listing, the Company has maintained a cumulative payout ratio, highlighting its long-term investment value.

We forecast that Yutong's EPS in 2026/2027/2028 will be RMB2.71/3.13/3.46 yuan, our target price is set unchanged at RMB43.5. It is equivalent to a prospective 2025/2026/2027 PE of 16/13.9/12.6x respectively. We give "BUY" rating. (Closing price as at 28 April)

"P/E

Source: Wind, Phillip Securities Hong Kong Research

Financials

"Financial

(Closing price as at 28 April)

Download PDF Version...




Recommendation on 29-4-2026
RecommendationBUY (Maintain)
Price on Recommendation Date$ 35.630
Suggested purchase priceN/A
Target Price$ 43.500
Writer Info
Zhang Jing
(Analyst)
Tel: +86 021-6351 2939
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]